Comparison of linezolid regimens, in addition to bedaquiline and pretomanid, for the management of drug-resistant tuberculosis (the ZeNix study): Critical reading
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.162.1800Keywords:
Extensively Drug-Resistant Tuberculosis, Bedaquiline, Pretomanid, LinezolidAbstract
Presentation: In this article we present our critical appraisal of a randomized clinical trial published in the New England Journal of Medicine in 2022. Study conclusions: The study compares four linezolid regimens (in addition to bedaquiline and pretomanid) for the management of drug-resistant tuberculosis. Finally, it shows that the regimen of 600 mg of linezolid for 26 weeks had less frequency of therapeutic failure and adverse events (compared to giving it for fewer weeks or at higher doses). Critical comment: The article is relevant because the appropriate dose of linezolid and duration of treatment with this agent to minimize adverse effects and maintain efficacy against highly resistant tuberculosis is still unclear. Despite some limitations such as low number of participants, high loss to follow-up, and no statistical comparisons between groups, the results are relatively reliable for decision making.
Downloads
Metrics
References
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for drug-resistant tuberculosis. N Engl. J. Med. 2022; 387 (9), 810–823. doi: 10.1056/NEJMoa2119430
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Protocole Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis [Internet]. N Engl J Med. 2022 [citado 30 de noviembre del 2022];387(9):810-23. Recuperado a partir de: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2119430/suppl_file/nejmoa2119430_protocol.pdf
Jiang H, Liu M, Zhang Y, Yin J, Li Z, Zhu C, et al. Changes in Incidence and Epidemiological Characteristics of Pulmonary Tuberculosis in Mainland China, 2005-2016. JAMA Netw Open. 2021;4(4):e215302. doi: 10.1001/jamanetworkopen.2021.5302
Sachdeva KS. Accelerating progress towards ending tuberculosis in India. Indian J Med Res. 2020;151(4):266-8. doi: 10.4103/ijmr.IJMR_407_20
Organización Panamericana de la Salud (OPS). Tuberculosis en las Américas 2018. 2018 [Internet]. [citado 24 de febrero de 2023]. Recuperado a partir de: https://iris.paho.org/bitstream/handle/10665.2/49510/OPSCDE18036_spa?sequence=#:~:text=En%20las%20Am%C3%A9ricas%2C%20la%20tasa,Am%C3%A9rica%20(3%2C3)
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. doi: 10.1056/NEJMoa1901814
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis [Internet]. World Health Organization. 2013 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://www.who.int/publications/i/item/9789241505482
López Tricas. Tuberculosis en Sudáfrica. Estudio NIX-TB [Internet]. info-farmacia.com. 2019 [citado 30 de noviembre de 2022]. Recuperado a partir de: http://www.info-farmacia.com/microbiologia/tuberculosis-en-sudafrica-estudio-nix-tb
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. doi: 10.1136/bmj.d5928
Bonnett LJ, Ken-Dror G, Davies GR. Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review. Trials. 2018;19(1):134. doi: 10.1186/s13063-018-2522-x
World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. 2014 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://apps.who.int/iris/handle/10665/79199
Lee S, Lee Y, Lee S, Islam SMS, Kim SY. Toward Developing a Standardized Core Set of Outcome Measures in Mobile Health Interventions for Tuberculosis Management: Systematic Review. JMIR MHealth UHealth. 2019; 7(2):e12385. doi: 10.2196/12385
World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. World Health Organization. 2022 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://www.who.int/publications-detail-redirect/WHO-UCN-TB-2022-2
Thwaites G, Nguyen NV. Linezolid for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):842-3. doi: 10.1056/NEJMe2208554
ICMJE Form for Disclosure of Potential Conflicts of Interest [internet]. [citado 30 de noviembre de 2022]. Recuperado a partir de: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2119430/suppl_file/nejmoa2119430_disclosures.pdf
Dheda K. An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NEXT) [internet]. clinicaltrials.gov. 2021 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://clinicaltrials.gov/ct2/show/NCT02454205
Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). Am J Respir Crit Care Med. 2022;205(10):1214-27. doi: 10.1164/rccm.202107-1779OC
Global Alliance for TB Drug Development. A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis [internet]. clinicaltrials.gov. 2020 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://clinicaltrials.gov/ct2/show/NCT02333799
Medecins Sans Frontieres, Netherlands. Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial (PRACTECAL-PRO) [internet]. clinicaltrials.gov. 2021 [citado 30 de noviembre de 2022]. Recuperado a partir de: https://clinicaltrials.gov/ct2/show/NCT03942354
TB-PRACTECAL: MSF clinical trial finds short, effective and safe drug-resistant tuberculosis treatment [Internet]. Médecins Sans Frontières (MSF/Doctors Without Borders). 2021 [citado 11 de diciembre de 2022]. Disponible en: https://msf-seasia.org/news/tb-practecal-msf-clinical-trial-finds-short-effective-and-safe-drug-resistant-tuberculosis
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Frank Zela-Coila, Carlos Cabrera-Cruzado, Nicole Stephanie Baquerizo-Quispe, Margarita Liz Alvarez-Vilchez, Alvaro Taype-Rondan
This work is licensed under a Creative Commons Attribution 4.0 International License.
